<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01756976</url>
  </required_header>
  <id_info>
    <org_study_id>TP-CLN-100257</org_study_id>
    <nct_id>NCT01756976</nct_id>
  </id_info>
  <brief_title>Clinical Evaluation of the OrthoPAT Advance System</brief_title>
  <official_title>Clinical Evaluation of the OrthoPAT Advance System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haemonetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Haemonetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is intended to provide additional performance data of the OrthoPAT Advance in
      routine orthopedic surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The OrthoPAT Advance system is being developed by Haemonetics to change the user interface,
      especially for adding calculations for Estimating Blood Loss- (EBL). The OrthoPATÂ® serves as
      the predicate device. The following items will be changed in the OrthoPAT Advance system
      compared to OrthoPAT:

        -  Software &amp; User Interface - ability to enter irrigant and anti-coagulant volumes and
           allow Estimated Blood Loss (EBL) calculation to be made by OrthoPAT Advance.

        -  Hardware -

             -  Redesign of reservoir and filter to process blood earlier by reducing hold-up
                volume and improve fluid visualization in reservoir.

             -  Extended battery life.

      It is not intended to validate the major changes in the OrthoPAT Advance device (reservoir /
      filter and EBL), which will be conducted as lab based tests. The correct functioning of the
      reservoir / filter and EBL changes will be confirmed in the clinical setting in this study.
      However the most rigorous challenge to the filter will be by presenting the worst case media
      and this can only be controlled in the laboratory.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Washed RBC Hematocrit</measure>
    <time_frame>&lt; 4 hours</time_frame>
    <description>The Hematocrit of the RBC shall be &gt; 50%.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Transmission, Blood, Recipient/Donor</condition>
  <arm_group>
    <arm_group_label>Investigational Device</arm_group_label>
    <description>The 510k cleared OrthoPAT Advance will be used in this standard of care arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <description>The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OrthoPat Advance</intervention_name>
    <description>The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.</description>
    <arm_group_label>Investigational Device</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects scheduled for hysterectomy or orthopediac procedures.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female over the age of 18 years

          -  Subject is scheduled for a total knee/hip replacement/ revision or a hysterectomy.

          -  Subjects determined eligible per site standard of care for use of intra- and
             post-operative use of cell salvage device

        Exclusion Criteria:

        For subjects where product is transfused

          -  Subject is undergoing a trauma procedure where there is a possibility of contamination
             from an open wound.

          -  Patient is diagnosed with sepsis.

          -  Patient is diagnosed with sickle-cell anemia.

          -  Malignant cells may be mixed with blood salvaged from the surgical field.

          -  Prostatic or amniotic fluid is mixed with blood salvaged from the surgical field.

          -  Blood salvaged from the surgical field may be contaminated from an active infection at
             wound/drain site.

          -  Blood salvaged from the surgical field contains topical hemostatic agents,
             anti-bacterial agents, or wound irrigants not intended for parenteral use.

        For all subjects:

          -  Subject is undergoing a procedure which involves high, rapid blood loss such as liver
             transplants, certain cardiovascular procedures, and trauma procedures where blood loss
             is high (per Investigators judgment).

          -  Any procedure terminated prior to completion by subject request, operator decision or
             error, or device error.

          -  Any subject with which at least 200mL of filtered blood or 1 full disc is not
             available for processing and data collection within the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Waters, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Medial Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2012</study_first_submitted>
  <study_first_submitted_qc>December 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2012</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>September 17, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 20, 2013</results_first_posted>
  <last_update_submitted>September 17, 2013</last_update_submitted>
  <last_update_submitted_qc>September 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Investigational Device</title>
          <description>The 510k cleared OrthoPAT Advance will be used in this standard of care arm.</description>
        </group>
        <group group_id="P2">
          <title>Control Group</title>
          <description>The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Investigational Device</title>
          <description>The 510k cleared OrthoPAT Advance will be used in this standard of care arm.</description>
        </group>
        <group group_id="B2">
          <title>Control Group</title>
          <description>The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="84"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" spread="19"/>
                    <measurement group_id="B2" value="46" spread="9"/>
                    <measurement group_id="B3" value="55" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Washed RBC Hematocrit</title>
        <description>The Hematocrit of the RBC shall be &gt; 50%.</description>
        <time_frame>&lt; 4 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Investigational Device</title>
            <description>The 510k cleared OrthoPAT Advance will be used in this standard of care arm.</description>
          </group>
          <group group_id="O2">
            <title>Control Group</title>
            <description>The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.</description>
          </group>
        </group_list>
        <measure>
          <title>Washed RBC Hematocrit</title>
          <description>The Hematocrit of the RBC shall be &gt; 50%.</description>
          <units>percentage of HcT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.43" spread="7.47"/>
                    <measurement group_id="O2" value="56.48" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Investigational Device</title>
          <description>The 510k cleared OrthoPAT Advance will be used in this standard of care arm.</description>
        </group>
        <group group_id="E2">
          <title>Control Group</title>
          <description>The commercially available OrthoPAT will be used in this arm. This is an observational trial and there is no intervention.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Project Manager</name_or_title>
      <organization>Haemonetics</organization>
      <phone>781-356-9595</phone>
      <email>michael.dioguardi@haemonetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

